Welcome to Gyre Therapeutics
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
More news
